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Summary
Objective: To assess the influence of drug resistance on treatment outcome among patients treated with Category-II regimen
and document drug susceptibility pattern of “Failures” to this regimen.
Design:  A retrospective analysis of patients registered  from May 1999 through December 2004.
Results: Treatment success was 42%  among 572 patients and was similar among patients with fully susceptible or resistant but
non-MDR organisms (41% of 254 and 40% of 128 patients, respectively). Among 49 MDR-TB patients, 27% had successful
treatment outcome. The failure rates among patients with fully susceptible, resistant but non-MDR and MDR bacilli, were 6%,
12% and 27% respectively. Default was significantly higher among males (53% vs. 34%: p<0.01) smokers (57% vs. 36%: p
<0.001), alcoholics (58% vs. 39%: p <0.001) and   patients with higher initial smear grading (2+ or 3+, 56% vs. scanty or 1+,
44%:  p <0.01). DST results were available for 60% (31 of 52) of failures and 10 had MDR-TB.
Conclusion: The low success rate to the re-treatment regimen was mainly due to non-compliance. Failure was observed among
9% of patients and MDR-TB was 32% among Category II failures.  The currently recommended Category II regimen appears
to be adequate for majority of re-treatment cases.
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BACKGROUND
The Revised National Tuberculosis Control
Programme (RNTCP) based on the globally
recommended Directly Observed Treatment-Short-
course (DOTS) strategy was implemented in India
in a phased manner since 1993. Treatment outcome
among new smear-positive pulmonary tuberculosis
(PTB) patients to category-I regimen has been
reported to be good with a success rate of 83% or
higher at national level 1, 2.  For previously treated
patients, the success rate to the re-treatment regimen
(CAT-II) was low (71%). Among patients typed as
‘failure’ and treated with re-treatment regimen, risk
of subsequent failure was higher, compared to other
types1, 2.
There is concern regarding the effectiveness
of category-II (CAT-II) regimen for re-treatment
cases especially for ‘Failures’3,4.  Whether or not this
re-treatment regimen is appropriate depends on the
prevalence of drug resistance among these cases and
treatment adherence. In India, it is reported that,
1-3.4% of new patients have had multi-drug resistant
TB (MDR TB)5. Studies on acquired resistance  have
shown  rates of resistance to Isoniazid ranging from
34.5-67%, for Streptomycin around 25% and for
Rifampicin from 2.8-37.3%6.
Tuberculosis Research Centre (TRC) has
been monitoring the DOTS programme in one
Tuberculosis Unit (TU), Tiruvallur district, Tamil
Nadu. This paper describes the treatment outcome
among different types of patients admitted to the re-
treatment regimen, the influence of drug resistance
on treatment outcome and the drug susceptibility
pattern among patients who failed to this regimen.
METHODOLOGY
Tuberculosis Research Centre (TRC) is
undertaking a series of epidemiological surveys
(Disease and tuberculin surveys to estimate
prevalence of TB and infection) in an area of
Tiruvallur district since 1999.  RNTCP was
implemented by Government of Tamil Nadu in this
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area and TRC was monitoring the same up to 2004
December.  Monitoring and follow up were done
according to RNTCP guidelines7.  Definitions
recommended under RNTCP were followed to define
treatment outcomes. As an operational study, we
have been conducting Drug Resistance Surveillance
(DRS) of patients treated under RNTCP in this area.
Drug sensitivity testing (DST) was done for all
patients at the initiation of treatment and whenever
they produced a positive smear during the treatment
period.  HIV screening was not done since it is not
recommended under RNTCP. This paper gives the
findings of a retrospective analysis of patients
registered under category II regimen of RNTCP.
Study area and population
The study area has a population of 580,000
spread over 209 villages and 9 urban clusters, situated
about 45 kilometres from Chennai. The area has 17
governmental health care facilities, including 7
designated microscopy centres. Smear positive
patients, with history of previous anti-tuberculosis
treatment for more than one month, comprising cases
of ‘Failure’, Treatment after Default (‘TAD’), and
‘Relapse’ started on the CAT-II regimen from 1999
to 2004, constituted the study population. For
outcome of treatment, we have included patients
registered up to December 2003 since TRC was
monitoring the programme only up to December
2004.
Setting
Patients attending any of the health facilities
with a history of cough for 3-weeks or more, were
screened for tuberculosis by sputum smear
microscopy (Ziehl-Neelsen method). Diagnosis,
treatment and monitoring were done according to
RNTCP guidelines7,8.  The standard re-treatment
regimen of RNTCP in India  consists of 3 months of
Isoniazid (H), Rifampicin(R), Pyrazinamide(Z), and
Ethambutol(E), with addition of Streptomycin (S)
in the initial two months, followed by 5 months of
R, H and E (2SHRZE3/1EHRZ3/5HRE3) given three
times a week, throughout the 8 months period .
Patients whose sputum smears remained positive at
the end of intensive phase of three months, treatment
with R, H, Z and E was extended for one more
month.
Drug sensitivity testing
Two additional sputum specimens were
collected for drug sensitivity tests (DST) within one
week of starting treatment and whenever they
produced a positive sputum by smear microscopy,
during treatment. The sputum samples were
processed for culture for M. tuberculosis on
Lowenstein - Jensen medium9. Cultures positive for
M.tuberculosis were subjected to indirect sensitivity
test for H, R, E and S. The resistance to H and R
was determined by absolute concentration method
(MIC) and to S by Resistance Ratio (RR)
methods10,11.  An MIC of 5mg/L or more, 8mg/L or
more and  an MIC of 128mg/L or more were defined
as resistance for H, E and R respectively  and  an
RR of 8 or more was considered as resistance to
streptomycin..
Statistical analysis
The data were scrutinized for completeness
and all the records were keyed in twice. Chi-square
test of significance was performed to test the
difference between different proportions. Yates
corrected two-tailed P values <0.05 were considered
as significant. The potential risk factors for default
were studied by univariate analysis using Epi Info
version 6.04 d (Centers for Disease Control, Atlanta,
GA, 2001).
RESULTS
From May 1999 through December 2004,
a total of 697 smear-positive patients were started
on re-treatment with CAT-II regimen. The proportion
of smear-positive re-treatment cases to the total
smear-positive cases ranged from 24.5% in 1999 to
22.8% in 2004.  The 697 patients included - 32%
cases of ‘Relapse’, 20% ‘Failure’ and 47% ‘TAD’
cases.
Treatment outcome according to ‘type’ of cases
Of the 697 smear-positive patients registered
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to CAT-II regimen, 575 patients whose treatment
outcome was available by December 2004 are
included in the analysis (Table 1). (Three cases
belonging to the type “others” were excluded from
analysis, since the number was very few and they
could not be combined with any other group for
analysis.). Of the total 572 cases, 238 (42%) had a
successful treatment outcome (cure-41%, treatment
completed-1%) and 240 (42%) defaulted. ‘Relapse’
cases had a significantly higher cure rate (51%)
compared to ‘Failure’ and TAD cases (p <0.01).
Fifty-two (9%) patients failed to the re-treatment
regimen; 14% (15 of 111) among ‘Failures’, 8% (15
of 187) among ‘Relapses’, and 8% (22 of 274)
among ‘TAD’ cases. However the difference was
not statistically significant. The time at which patients
defaulted were available for 219 out of the total 240
from the treatment cards and 49% defaulted within
the first 3 months of treatment. The rate and time of
default were almost similar in all types of patients.
Forty-one (7%) patients died during the course of
the treatment. Of the 37 patients for whom
information is available, 70% died within 3 months
of starting treatment.
Response to treatment according to drug
susceptibility pattern
Of the 572 cases included in this analysis,
even though it was planned to collect sputum
specimens from all patients, specimens could not be
collected from 50 (9%) patients within one week of
treatment initiation due to operational reasons. Among
431 patients who produced positive cultures, 254
(59%) harboured sensitive bacilli, 128 (30%) resistant
but non-MDR bacilli, and 49 (11%) had MDR-TB
(Table 2). There was no growth in the culture for
91 (17%) patients.  Among 254 patients harbouring
sensitive bacilli and 128 with resistant but non-MDR
bacilli, the cure rates (41%, 40%) were almost
similar. Among 49 patients with MDR-TB, 13 (27%)
had a favourable outcome. The failure rates were
6%, 12% and 27% among patients with fully
susceptible, resistant but non-MDR and MDR bacilli,
respectively. The failure rate was highest among
patients with MDR-TB (p<0.05). The default rate
was high and almost similar in all groups (46%, 38%,
and 39%), irrespective of the drug susceptibility
profile. The MDR-TB observed was 9% (20 of 226),
22% (14 of 63), and 11% (15 of 142) among TAD,
‘Failures’, and ‘Relapses’ respectively (Table 2). The
MDR-TB observed among ‘Failures’ was
significantly higher (22%) compared to that observed
in the other two types of patients (p<0.05).
Among the 91 (17%) patients who produced
no growth in the culture, 56% had a successful
treatment outcome, 35% defaulted, 3% died and 5%
failed. Of the 111 ‘Failure’ cases registered to the
CAT-II regimen, sputum specimens were collected
from 94 cases. Thirty-one of the 94 (33%) ‘Failure’
cases did not show any growth in the culture.
Considering all 94 ‘Failure’ cases for whom sputum
specimens were collected, MDR-TB could be
documented in 14 (15%) of the cases, compared to
22% considering only patients with growth in culture.
The culture negativity among TAD and Relapse cases
was 12% (30/256) and 17% (30/172) respectively.
Table 1: Treatment outcome of 572 re-treatment cases registered to CAT II regimen.
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Treatment Outcome 






No.       % No.    % No.      % No.     % No.  % 
Relapse  187 96       51 15       8  66        35 9         5 1       1 
Failure 111 36       32  15      14 51        46  9         8 0       0 
TAD 274 106     39 22       8 123      45 23       8  0      0 
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We analysed risk factors for default for 42%
of patients who had defaulted. In univariate analysis,
of treatment success vs default, a higher default was
significantly associated with sex {66% (47 of 71)
among females vs 47% (193 of 410) among males:
P<0.01}, smoking {64% (106 of 166) among non-
smokers vs 43% (83 of 195) among smokers:
P<0.001}, alcoholism {56% (112 of 199) among
non-users vs 42% (68 of 162) among users,
P<0.001} and initial smear grading {56% (112 of
216) with scanty or 1+ smears vs 44% (118 of 265)
with 2+ or 3+ smears, P<0.01}.
Sputum smear-positivity at the end of 3 or 4
months of treatment
Of the 572 re-treatment patients, sputum
smear results at the end of three months were not
available for 153 (27%) patients (126 defaulted and
27 died during the intensive period). One hundred
(17%) remained sputum smear-positive at the end
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Table 2:  Treatment outcome related to drug sensitivity pattern (n=431)
Success Default Died Failed Total  
Drug sensitivity results No.        % No.        % No          % No.        % N           %* 
TAD  
    Sensitive   
   Resistant (non-MDR) 
   
HR resistant      
  Total 
 
55      38 
24      39 
  6     (30) 
85      38 
 
68      47 
23      37 
   8      (40) 
99      44 
 
11       8 
  7     11 
   2     (10) 
20       9 
 
10       7 
  8      13 
   4      (20) 
22        9 
 
144       64 
   62        27 
  20         9 
   226 
Failure 
    Sensitive 
   Resistant (non-MDR) 
   HR resistant   
   Total 
 
    4       (21) 
11       37 
   1        (7) 
16      25 
 
12     (63) 
    12     40 
  6     (43) 
30     48 
 
2      (11) 
4        13 
2      (14) 
8        13 
 
 1        (5) 
     3        10 
    5        (36) 
   9        14 
 
19         30 
30         48 
14         22 
   63 
Relapse   
  
Sensitive  
 Resistant (non-MDR) 
  HR resistant    
  Total  
 
46      51 
16      42 
    6      (40) 
68      48 
 
37      41 
13      36 
    5      (33) 
55      39 
 
5        5 
3        8 
  0        (0) 
8        6 
 
3         3 
     4       11 
 4       (27) 
   11       8 
 
91         64 
36         25 
15         11 
 142 
Grand     Total 
Sensitive to H&R 




105    41 
51    40 
13    27 
169    39 
 
117    46 
48     38 
19     39 
184    43 
 
18        7 
14      11 
4        8 
36        8 
 
    14       6 
    15      12 
    13      27 
    42      10 
 
254          59 
128          30 
49          11 




*Percentage to the column total
  Figures in parenthesis indicate the denominator <25
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of three months of treatment (Table 3) and intensive
phase of treatment was extended for one more
month. Of these 100 patients, 34 patients remained
sputum smear positive at the end of four months of
treatment. A higher proportion (31%) of’ ‘Failure’
cases remained sputum smear positive at the end of
3 months of treatment compared to other types of
patients (16% for TAD, 11% for Relapses). Of the
100 patients who remained sputum smear-positive
at the end of 3 months of treatment, 26% were cured,
25% failed, 6% died and 43% defaulted.
Drug susceptibility profile among patients with
positive smear during treatment
Of the 100 patients who remained sputum
smear positive at the end of three months of
treatment, 26% (24 of 91 patients) had MDR-TB at
the time of starting treatment. At the end of third
month of treatment, of the 53 cases for whom
sputum was collected, 12 (23%) had MDR-TB and
17 (32%) had no growth on the culture (Table 4). At
the end of 4 months of treatment, 34 (6%) patients
Table 3. Sputum smear-positivity at the end of 3 or 4 months of treatment
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Table 4: Drug susceptibility profile of patients who produced positive sputum at 3 months, 4 months
and at the time of failure
Figure in parenthesis indicates the denominator <25
*Including one patient in each who was initially non-MDR (both H resistant)
 
 Sputum smear results after starting treatment 




No      %   
Positive  
No      %    
  N.A. 
No    %  
Negative 
No 
Positive   
No 






TAD 143    52 45      16 86     31 15 13 17 274 
Failure  51     46 34      31 26     23 8 15 11 111 
Relapse 125    67 21      11 41     22 8 6 7 187 
Total 319    56 100    17 153   27 31 34 35 572 
 
145
Sensitivity Positive at 3-m Positive at 4-m Failed
pattern (N=100) (N=34) (N=52)
Initial At 3-m Initial At 4-m Initial At Failure
Sp. not collected 8 45 3 11 5 18
Cul. Contaminated 1 2 1 1 0 3
         Total 9 47 4 12 5 21
No.  % No.  % No.  % No.  % No.  % No.    %
Cul Neg. 12   13 17    32 2      7 2       9 5      11 4       13
H & R – Sensitive 28   31 12    23 6      20 3      14 15    32 9       29
Resistant but
  Non-MDR 27   30 12    23 12    40 8      36 14     30 8       26
RH resistant 24   26 12    23 10    33 9*    41 13     28 10*   32
        Total               91                 53                 30               22                  47              31
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remained sputum smear positive. The drug sensitivity
results showed that, 33% of 30 cases (sputum not
collected from four cases) had MDR-TB initially and
at fourth month, of the 22 cases for whom DST
results were available, 9 (41%) had MDR-TB
including one who was initially non-MDR, and 9%
had negative culture.
Fifty-two patients who remained smear
positive at the end of fifth month or later during
treatment were declared ‘failed’ to the CAT-II
regimen. Drug susceptibility profile at the initiation
of re-treatment is available for 47 and 13 (28%) had
MDR-TB. At the time of failure, of the 31 cases for
whom sputum specimens were collected, 10 (32%)
had MDR-TB (including one who was initially non-
MDR). Of these 52 ‘Failures’, 27 patients had
converted to sputum smear negativity at the end of
intensive phase.
DISCUSSION
The proportion of smear-positive re-
treatment cases in this DOTS implemented area, over
a period of 5 years, from 1999 through 2004, did
not show any significant changes and it ranged from
24.5% in 1999 to 22.9% in 2004. Among the re-
treatment TB patients, nearly 50% constituted
patients who came for re-treatment after defaulting
to the previous regimen.
The low success rate (42%) to the CAT-11
regimen was mainly due to the high default (42%)
during treatment. If all these defaulted patients (240)
also had been regular for treatment, the treatment
success would have been 72%.  Another important
finding revealed in this analysis is that the prevalence
of drug resistance (non-MDR as well as MDR) was
almost similar initially and at the time of failure.
Development of resistance to Rifampicin among
patients who failed to CAT II regimen was low (2
patients with initial resistance to H emerged resistance
to R.)
The favourable outcome to the re-treatment
regimen was similar among patients with TB due to
susceptible and resistant but non-MDR bacilli. The
failure rates were 6%, 15% and 27% among patients
with fully susceptible, resistant but non-MDR and
MDR bacilli, respectively, suggesting the re-treatment
regimen had been effective in a majority of patients.
However, it may not be adequate for patients with
multi-drug resistant TB. Similarly in a retrospective
cohort study of patients enrolled into the WHO /
IUATLD global project on drug resistance surveillance
in 6 countries, Espinal et al12 has reported that of the
876 re-treatment cases, 44.5% were drug resistant,
including 19% of MDR-TB. Among them, 57% had
a successful outcome, 6% died, and 14% failed. And
failure rates among re-treatment cases were higher
in those with multi-drug resistant TB and with any
Isoniazid resistance other than multi-drug resistance.
High default rate (42%) was the major
reason for the low cure rate in this area. Default rate
was similar in all groups of patients, irrespective of
the type of patients or their drug resistance pattern.
The success rate (42%) for the re-treatment cases
in this report is significantly low compared to the
national average of around 70%1,2.  However, our
findings are comparable to that reported by Sophia
Vijay et al13 from Bangalore (resistance to any drug
40%, MDR-TB 12.8%, cure rate 39.8%, default rate
43.8%).
There is concern regarding the efficacy of
CAT-II regimen for re-treatment of TB patients
especially for ‘Failure’ cases, since  a high proportion
of them may be having MDR-TB. The prevalence
of multi-drug resistant TB in re-treatment patients in
this area was 11% and it was higher (22%) among
‘Failure’ cases. Few studies have reported very high
rates of MDR-TB in patients who fail to CAT-I
regimen. A case-control study from Peru,14  reported
a cure rate of 93% to CAT-I (2EHRZ/4R2H2), and
nearly 75% MDR-TB among failures to this regimen.
Treatment failure in urban Lima has been identified
as a strong predictor of MDR-TB. Quy et al15 from
Vietnam has reported that of the 40 failure cases to
CAT-I regimen (2SHRZ/6EH), 80% had MDR-TB.
Among 39 relapse cases, 8% had MDR-TB.  Cure
rate among relapse cases was 82.5%, while among
119 failure cases, the cure rate was 47% with 39%
of patients failing to the regimen. A report from
Malawi16 has reported a treatment outcome of 65%
for patients with recurrent TB, 81% of CAT-II
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patients had susceptible organisms and MDR-TB was
observed only in 4% of cases. In a retrospective
study Gninafon et al17, from Cotonou, Benin, has
reported satisfactory and comparable success rates
among re-treatment patients (78%) and new cases
(82%). The success rate was similar among relapses
(80%) and failures (85%). The failure rate for all re-
treatment patients was low (3%). The reasons
attributed for the excellent results by the authors were
the low rate of both primary (0.3%) and secondary
(11%) multi-drug-resistance and Rifampicin was
given only under strict supervision. Response to the
WHO-recommended re-treatment regimen varies
great deal between countries, depending on the
prevalence of drug resistance among these patients
and the quality of TB control.
Treatment compliance is the most crucial
factor for the successful outcome of any effective
regimen. Default was significantly more among male
patients, alcoholics and smokers. These groups of
patients need to be targeted with additional health
education and intensive counselling and supervision.
In TB cases with MDR-TB the standard
retreatment regimen result in unacceptably high failure
rates12 and for all other drug resistant forms of TB,
Rifampicin-based short course chemotherapy gives
satisfactory results18.  This study also shows that the
RNTCP policy in India of treating all re-treatment
cases with the WHO recommended re-treatment
regimen may be adequate except for the MDR-TB
patients.  DST should be done for patients who
remain sputum smear positive during the re-
treatment period and appropriate regimens should
be started as early as possible for better treatment
outcome and to reduce transmission of drug
resistant TB. Of the patients who remained sputum
smear-positive at the end of 3 and 4 months of
treatment, 23% and 41% respectively had MDR-TB.
Among the patients who failed to CAT-II regimen, 32%
had MDR-TB.  The limitations of this report are high
default rate and DST could not be done for a significant
number of cases who remained smear positive during
treatment. However, the initial drug susceptibility profile
was similar among patients for whom sputum was
not collected to those from whom sputum was
collected. The results are from a localized area and
need to be confirmed from other areas as well.
CONCLUSION
The low success rate to the CAT-II
regimen was mainly due to the high default
during treatment. If treatment compliance can
be ensured for all patients majority of patients
registered to CAT-II regimen can have a
successful treatment outcome.  Development of
resistance to Rifampicin observed among failures
to CAT II regimen was low.  A high proportion of
patients who failed to CAT-II regimen had either
susceptible or resistant but non-MDR bacilli. The
high default rate observed in the study area
suggests the need for enhanced counselling and
supervision with targeted health education.
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